The role of blood groups in the development of diabetes mellitus after gestational diabetes mellitus

Hatice Karagoz¹
Abdulsamet Erden²
Ozerhan Ozer²
Kubra Esmeray²
Ali Cetinkaya²
Deniz Avci²
Samet Karahan²
Mustafa Basak²
Kadir Bulut³
Hasan Mutlu³
Yasin Simsek⁴

¹Internal Medicine Department, Acibadem Kayseri Hospital, ²Internal Medicine Department, ³Medical Oncology Department, ⁴Endocrinology Department, Kayseri Training and Research Hospital, Kayseri, Turkey

Introduction: Gestational diabetes mellitus (GDM) is a common condition that is defined as glucose intolerance of varying degree with onset or first recognition during pregnancy and it affects approximately 5% of all pregnancies all over the world. GDM is not only associated with adverse pregnancy outcomes such as macrosomia, dystocia, birth trauma, and metabolic complications in newborns, but it is also a strong predictor of transitioning to overt DM postpartum. The association of ABO blood groups with DM has been observed before in several epidemiological and genetic studies and resulted with inconsistent findings, but still there are not enough studies in the literature about the association of ABO blood groups with GDM. In this study, we aimed at investigating any possible relationship between the ABO blood group system and GDM and also the transitioning of GDM to overt DM postpartum, in Turkey.

Patients and methods: A total of 233 patients with GDM from Kayseri Training and Research Hospital between 2002 and 2012 were included in the study. The cases that have serologically determined blood groups and Rh factor in the hospital records were included in the study, and the patients with unknown blood groups were excluded. Patients were classified according to blood groups (A, B, AB, and O) and Rh status (+/−). GDM was diagnosed based on the glucose cut-points of the International Association of the Diabetes and Pregnancy Society Groups. The distributions of blood groups of the patients with GDM were compared with the distribution of blood groups of 17,314 healthy donors who were admitted to the Turkish Red Crescent Blood Service in our city in 2012.

Results: There was a significant difference between the patients with GDM and control group in terms of distribution of ABO blood groups. Blood group AB was found to be higher in the patients with GDM compared to the control group (P=0.029). When the patients were compared according to the development of DM, the ratio of group O was higher than others, while the ratio of group B was lower in the group developing DM (P=0.001). There was a significant difference between the groups – GDM patients with or without DM – in terms of distribution of ABO blood groups with Rh factor and the ratio of developing DM is found to be higher in patients with +Rh factor among all the blood groups except for group B (P=0.008).

Conclusion: In this study, we found a higher risk of GDM for the patients with blood group AB, which means that we have to be more careful on the follow-up of pregnant women with blood group AB. The patients with GDM of blood group O are under a higher risk of developing DM and also +Rh factor must be considered as another risk factor, so these patients should be closely followed postpartum by the oral glucose tolerance tests. To our knowledge, this is the first analysis that investigates the association between the ABO blood groups and transitioning to DM after GDM.

Keywords: gestational diabetes mellitus, ABO blood groups, Rh factor
Introduction

Gestational diabetes mellitus (GDM) is a common condition that is defined as glucose intolerance of varying degree with onset or first recognition during pregnancy.1 GDM affects approximately 5% of all pregnancies all over the world and 135,000 pregnancies per year in the USA. Its incidence is increasing in parallel with the global increase in obesity and Type 2 diabetes mellitus (T2DM).2 GDM is not only associated with adverse pregnancy outcomes such as macrosomia, dystocia, birth trauma, and metabolic complications in newborns, but it is also a strong predictor of transitioning to overt DM postpartum.3,4

There are many screening tests defined by different associations for to determine GDM. A 50 g oral glucose challenge test (GCT) is the most widely accepted screening method for GDM in North America.5 The American Diabetes Association (ADA) published new recommendations for the detection and diagnosis of GDM in 2011, and these new criteria were based on the consensus opinion of the International Association of the Diabetes and Pregnancy Society Groups (IADPSG).6 IADPSG and ADA recommends a 75 g GCT for screening at 24–28 weeks’ gestation and a diagnosis of GDM is made when one or more glucose values fall at or above the specified thresholds: fasting glucose level: ≥5.1 mmol/L (92 mg/dL), 1 hour: ≥10.0 mmol/L (180 mg/dL), 2 hours: ≥8.5 mmol/L (153 mg/dL).

The ABO blood group system was first discovered by Karl Landsteiner in 1900. The blood group of a person depends upon the presence or absence of two genes, A and B. The gene is located on chromosome 9 and is called ABO glycosyltransferase.7

No diseases are known to result from the lack of expression of ABO blood group antigens, but the susceptibility to a number of diseases has been interrelated to ABO phenotype. For example, gastric cancer is found to be more common in blood group A individuals, whereas gastric and duodenal ulcers occur more commonly among the O blood group individuals.8

The association of ABO blood groups with DM has been observed before in several epidemiological and genetic studies and resulted with inconsistent findings.8–11 Group A was found to be associated with DM in some studies, but still there is not enough study in the literature about the correlation of ABO blood groups with GDM.12,13 In this study, we aimed at investigating any possible relationship between the ABO blood group system and GDM, in Turkey. In the second part of the study, we examined the relationship between the ABO blood group system and transitioning of GDM to overt DM postpartum.

Patients and methods

A total of 233 patients with GDM from Kayseri Training and Research Hospital between 2002 and 2012 were included in the study. This study was approved by the Kayseri Training and Research Hospital Ethics Committee. The cases that have serologically determined blood groups and Rh factor in the hospital records were included in the study, and the patients with unknown blood group were excluded. Patients were classified according to blood groups (A, B, AB, and O) and Rh status (+/−). All women had a GCT at 24–28 gestational weeks, and the patients with results of 2-hour plasma glucose level ≥140 were offered a 75 g oral glucose tolerance test (OGTT). GDM was diagnosed based on the glucose cut-points of the IADPSG criteria, that is, when any of the following glucose values was exceeded: fasting plasma glucose level ≥5.1 mmol/L (92 mg/dL) and/or 1-hour plasma glucose level ≥10 mmol/L (180 mg/dL) and/or 2-hour plasma glucose level ≥8.5 mmol/L (153 mg/dL). The patients who did not meet the diagnostic criteria were excluded.

The distributions of blood groups of the patients with GDM were compared with the distribution of blood groups of healthy donors that admitted to the Turkish Red Crescent Blood Service in our city in 2012. Donors consisted of 17,314 healthy volunteers. After comparing with the healthy control group, the patients with the diagnosis of GDM were examined for transitioning to overt DM postpartum by checking their drugs from the pharmacy data system in our country or by calling and inviting them to the hospital for the fasting glucose levels. The patients with fasting glucose levels ≥126 mg/dL at least twice or taking pharmacy for diabetes were accepted as DM.

Statistical analysis was performed using the SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). Qualitative variables are given as percent and for the correlation of the patients with GDM and control group from the point of ABO blood groups. The relationship between the groups of GDM and DM patients following GDM was examined by the chi-square test. A P-value <0.05 was considered significant.

Results

The mean age of all patients with GDM was 32.45±5.14 years. The percentages of patients with GDM for O, A, B, and AB groups were 26%, 45%, 17%, and 12%, whereas those of control group (healthy donors) were 31%, 45%, 16%, and 8%, respectively. In both of the groups, the ratio of the patients with blood group A was the highest, while the ratio of group AB was the lowest (Table 1). There was a significant
The pathogenesis of GDM is not yet completely defined. Genetic predispositions, environmental factors, and their interactions that are blamed for T2DM may also be the causes of GDM. Genetic variants related to regulation of insulin secretion and resistance were found to be significantly associated with a higher risk of GDM, in a meta-analysis. New studies on the roles of biomarkers for T2DM and GDM aimed at resolving the uncertainty on the pathogenesis of GDM. A study showed that the inflammation markers such as tumor necrosis factor-alpha and interleukin-6 could play a role in insulin resistance and development of GDM. Another study showed that the increase of inflammatory markers may be one of the first detectable disorders in healthy women at high risk of T2DM and insulin-resistance syndrome like those with a GDM history. Another study that aimed at evaluating the value of increasing inflammation in predicting GDM showed that maternal white blood cell, erythrocyte, and platelet counts are important correlates of GDM. Soluble cell adhesion molecules such as sE-selectin and sICAM-1 could be the markers of endothelial dysfunction that was reported to be a plausible important step in insulin resistance and T2DM, and so the elevated levels of these molecules might represent an early manifestation of endothelial dysfunction and independently predict development of T2DM. These biomarkers could also be implicated in the pathogenesis of GDM because of the similarity in pathogenesis between T2DM and GDM. There are many studies about the association of DM and ABO blood group systems in the literature. McConnell et al showed an association between DM and blood group A and this was confirmed by Andersen and Lauritzen. A recent study has demonstrated that blood group B is a protective factor against T2DM. A study from India showed an association of increased risk of DM and blood groups of A and AB. A study consisting of 792 Iranian pregnant women observed that women with blood group AB had higher fasting blood glucose in the second trimester than those with blood group A. But still there are not enough studies in the literature about the association of ABO blood groups with GDM. Because of the increasing prevalence of GDM and DM after GDM, we aimed at investigating any possible relationship between the ABO blood group system and GDM and also transitioning to DM.

Different percentages have been reported on GDM progression to T2DM postpartum in the literature depending on ethnicity and the proportion of participants with severe hyperglycemia during pregnancy. In a study Jang stated that 9% of predominantly Hispanic women with GDM developed

<table>
<thead>
<tr>
<th>ABO blood groups</th>
<th>Control group, n (%)</th>
<th>Patients with GDM, n (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>5,423 (45)</td>
<td>60 (26)</td>
<td>0.029</td>
</tr>
<tr>
<td>A</td>
<td>7,756 (19)</td>
<td>104 (45)</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>2,819 (16)</td>
<td>40 (17)</td>
<td></td>
</tr>
<tr>
<td>AB</td>
<td>1,316 (8)</td>
<td>29 (12)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>17,314 (100)</td>
<td>233 (100)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: GDM, gestational diabetes mellitus.

**Discussion**

The pathogenesis of GDM is not yet completely defined. Genetic predispositions, environmental factors, and their interactions that are blamed for T2DM may also be the causes of GDM. Genetic variants related to regulation of insulin secretion and resistance were found to be significantly associated with a higher risk of GDM, in a meta-analysis. New studies on the roles of biomarkers for T2DM and GDM aimed at resolving the uncertainty on the pathogenesis of GDM. A study showed that the inflammation markers such as tumor necrosis factor-alpha and interleukin-6 could play a role in insulin resistance and development of GDM. Another study showed that the increase of inflammatory markers may be one of the first detectable disorders in healthy women at high risk of T2DM and insulin-resistance syndrome like those with a GDM history. Another study that aimed at evaluating the value of increasing inflammation in predicting GDM showed that maternal white blood cell, erythrocyte, and platelet counts are important correlates of GDM. Soluble cell adhesion molecules such as sE-selectin and sICAM-1 could be the markers of endothelial dysfunction that was reported to be a plausible important step in insulin resistance and T2DM, and so the elevated levels of these molecules might represent an early manifestation of endothelial dysfunction and independently predict development of T2DM. These biomarkers could also be implicated in the pathogenesis of GDM because of the similarity in pathogenesis between T2DM and GDM. There are many studies about the association of DM and ABO blood group systems in the literature. McConnell et al showed an association between DM and blood group A and this was confirmed by Andersen and Lauritzen. A recent study has demonstrated that blood group B is a protective factor against T2DM. A study from India showed an association of increased risk of DM and blood groups of A and AB. A study consisting of 792 Iranian pregnant women observed that women with blood group AB had higher fasting blood glucose in the second trimester than those with blood group A. But still there are not enough studies in the literature about the association of ABO blood groups with GDM. Because of the increasing prevalence of GDM and DM after GDM, we aimed at investigating any possible relationship between the ABO blood group system and GDM and also transitioning to DM.

Different percentages have been reported on GDM progression to T2DM postpartum in the literature depending on ethnicity and the proportion of participants with severe hyperglycemia during pregnancy. In a study Jang stated that 9% of predominantly Hispanic women with GDM developed
T2DM in early postpartum while this ratio as 3% in a study population of predominantly white women and 10% in a population of predominantly black women. Furthermore, another author reported a 10% rate of developing DM in a population of predominantly black women.

In our retrospective examination of 233 patients with GDM, AB blood group seems to be a risk factor for the development of GDM. This finding was in contrast with a recent study from the People’s Republic of China. This study was a prospective cohort study of Chinese women and demonstrated that the women with blood group AB were less likely to have a positive GCT and GDM. These contrasting findings suggest that the association between the ABO blood groups and the risk of DM and GDM may differ by populations.

Among the patients with GDM, there was a significant risk of developing DM after GDM for the blood group O and a relative mild increase for the blood group AB.

On the other hand, the lower risk of developing DM after GDM among the patients with blood group B seems to be a protective factor at this point. Further studies are needed to understand the underlying biological base and the biological processes responsible for this protective effect.

Prior studies on the association of Rh factor with the risk of T2DM were rare and reported in consisted findings. Our study showed that Rh status is also another effective factor together with blood groups and +Rh factor could increase the risk for developing DM after GDM.

GDM is not only associated with acute increased risk for complications of pregnancy but also it has been associated with long-term disease risks for both mother and baby. Perinatal morbidity includes hyperinsulinaemia, macrosomia, hypoglycaemia, hyperbilirubinaemia, and respiratory distress syndrome, whereas long-term morbidity for the offspring includes obesity and diabetes independent of genetic factors, so it is important to determine all the etiological factors responsible for GDM in the follow-up of these patients.

Our study has some limitations. The first one being the retrospective nature of study and the other important limitation is the lack of knowledge about the following risk factors for postpartum DM: prepregnancy weight, body mass index, previous history of GDM, and a family history of DM in first-degree relatives.

Because the ABO/Rh blood group phenotypes are stable throughout life time, it is important to determine the association between the ABO blood groups and the risk of GDM because of the clinical implications. If our findings of this study can be replicated by other studies performed on other nations in larger patient populations, ABO blood group phenotypes may be used as a single risk factor or in combination with other risk factors to identify individuals at high risk for possible prevention of GDM before or at early pregnancy. However, further epidemiological and genetic studies are necessary to define the relationship between the ABO blood groups and GDM.

### Conclusion

In summary, this study found that the patients with blood group AB have a higher risk for GDM when the screening tests are performed among the normal population. This means that we have to be more careful on the follow-up of pregnant women with blood group AB. OGTT may be performed at earlier gestational weeks, or the patients may be invited to the hospital for glucose monitoring during the pregnancy, even if OGTT is normal.

Especially the patients with GDM of blood group O are under the higher risk of developing DM and also +Rh factor must be remembered as another risk at this point, so these patients should be closely followed postpartum by the OGTTs.

To our knowledge, this is the first analysis that investigates the association between the ABO blood groups and transitioning to DM after GDM.

### Table 3 Comparison of ABO blood groups and Rh factor between the GDM patients with or without DM

<table>
<thead>
<tr>
<th>ABO blood groups with Rh factor</th>
<th>GDM patients with DM, n (%)</th>
<th>GDM patients without DM, n (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 Rh (+)</td>
<td>12 (48)</td>
<td>39 (19)</td>
<td>0.008</td>
</tr>
<tr>
<td>0 Rh (-)</td>
<td>2 (8)</td>
<td>7 (3)</td>
<td></td>
</tr>
<tr>
<td>A Rh (+)</td>
<td>5 (20)</td>
<td>84 (40)</td>
<td></td>
</tr>
<tr>
<td>A Rh (-)</td>
<td>2 (8)</td>
<td>13 (7)</td>
<td></td>
</tr>
<tr>
<td>B Rh (+)</td>
<td>0 (0)</td>
<td>36 (17)</td>
<td></td>
</tr>
<tr>
<td>B Rh (-)</td>
<td>0 (0)</td>
<td>4 (2)</td>
<td></td>
</tr>
<tr>
<td>AB Rh (+)</td>
<td>4 (16)</td>
<td>19 (9)</td>
<td></td>
</tr>
<tr>
<td>AB Rh (-)</td>
<td>0 (0)</td>
<td>6 (3)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>25 (100)</td>
<td>208 (100)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: GDM, gestational diabetes mellitus.
Disclosure
The authors report no conflicts of interest in this work.

References